Sinomenine inhibits A549 human lung cancer cell invasion by mediating the STAT3 signaling pathway

SHULONG JIANG1,2*, YEBO GAO1,3*, WEI HOU1, RUI LIU1, XIN QI1, XIA XU2, JIE LI2, YANJU BAO1, HONGGANG ZHENG1 and BAOJIN HUA1

1Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053; 2Department of Oncology, Jining First People's Hospital, Jining, Shandong 272111; 3Beijing University of Chinese Medicine, Beijing 100029, P.R. China

Received March 19, 2015; Accepted April 8, 2016

DOI: 10.3892/ol.2016.4768

Abstract. Increasing evidence suggests that the failure of lung cancer treatment may occur as a result of tumor invasion and metastasis. Signal transducer and activator of transcription 3 (STAT3), an epithelial-mesenchymal transition-inducing transcription factor, is a key signaling molecule involved in the proliferation, apoptosis, invasion and metastasis of tumor cells. Sinomenine is an alkaloid compound with an antineoplastic potential against a variety of cancer cells. The aim of the present study was to assess the antitumor mechanisms of sinomenine in the A549 human lung cancer cell line. The results demonstrated that sinomenine manifested dose-dependent cytotoxicity and induced apoptosis in A549 cells. The protein expression of Janus kinase 2, STAT3, phosphorylated-STAT3, Snail, N-cadherin and vimentin decreased in sinomenine-treated cells, while E-cadherin protein expression increased. The regulation of STAT3, N-cadherin and E-cadherin by sinomenine was further confirmed by reverse transcription-quantitative polymerase chain reaction and immunofluorescent staining. It was demonstrated that sinomenine exerts inhibitory effects on A549 human lung cancer cell invasion, possibly through the inhibition of STAT3 signaling. These results provide a novel insight into the role of sinomenine in the treatment of non-small cell lung cancer.

Introduction

Lung cancer is one of the most common types of malignant tumor with a high mortality (1). Although surgical resection is currently the optimal treatment for lung cancer, treatment of this disease remains challenging as patients have not demonstrated long-term clinical benefits (2). According to the recent International Database, following complete resection of lung cancer, the 5-year survival rate of patients with lung cancer is 73% for pathological stage IA, 58% for stage IB, 46% for stage IIA, 36% for stage IIB and 24% for stage IIIA (3). The failure of combined chemotherapy and surgical resection is primarily attributed to cancer metastasis and invasion (4,5). Therefore, it is necessary to seek more effective anticancer agents targeting tumor invasion and metastasis.

Chronic inflammation is undeniably a contributing factor in tumour proliferation, survival, angiogenesis and metastasis (14-16). To date, the majority of studies investigating inflammation and cancer have focused on the regulatory network dominated by nuclear factor (NF)-xB and signal transducer and activator of transcription 3 (STAT3) (17-19). STAT3 is a key molecule in the promotion of tumorigenesis, functioning via chronic inflammation, and also in the process of cancer-related inflammation, which is able to regulate the biological behavior of cancer and immune cells through mediation of extracellular signaling of inflammatory factors (18). Given the roles of STAT3 in chronic inflammation, and the regulation of the initiation and resolution of epithelial-mesenchymal transition (EMT) in malignant cells (20,21), decreasing or blocking its activity may suppress malignant conversion. The present study hypothesized that...
sinomenine may be able to inhibit lung cancer invasion via modulation of the STAT3 signaling pathway; thus, the effect of sinomenine on STAT3 signaling and EMT biomarkers in A549 cells was investigated.

Materials and methods

Reagents. Sinomenine was obtained from the China's National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China), and was dissolved in dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA) as a stock solution. Cucurbitacin I, a potent pharmacological inhibitor of Janus kinase (JAK)/STAT3 was provided by Gene Operation (Ann Arbor, MI, USA).

Cell culture. The A549 human lung adenocarcinoma cell line was obtained from the General Medical Cell Center of Peking Union Medical College (Beijing, China). The cells were grown in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% inactivated fetal bovine serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.), and incubated at 37°C with 5% CO2.

Cell viability assay. Cell viability was analyzed in 96-well plates (Corning Incorporated, Corning, NY, USA) using Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). A total of 2x104 A549 cells/well were treated with the indicated concentrations of sinomenine or cucurbitacin I, which served as a positive control, for 24-72 h. Sinomenine was diluted by RPMI-1640 culture medium, and the final concentration was 0.125, 0.25, 0.5, 1.0 or 2.0 mM in turn. The action concentration of cucurbitacin I was 0.25 uM. Following treatment, 20 µl CCK-8 was added, and incubation continued for 1 h. The optical density was determined at the wavelength of 450 nm on a multi-mode microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

Annexin V staining. Apoptosis was determined using an fluor resin isothiocyanate (FITC) Annexin V apoptosis DTEC KIT (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. First, A549 cells were incubated with sinomenine for 24 and 48 h. The cells were collected and washed twice with cold PBS and then resuspended in 1X Binding Buffer at a concentration of 1x106 cells/ml. Subsequently, 100 µl of the suspension (1x105 cells) was transferred to a 5 ml culture tube, and 5 µl FITC-conjugated Annexin V with 10 µl propidium iodide (PI) were added. The cells were gently vortexed and incubated for 15 min at 25°C in the dark. Finally, 400 µl of 1X Binding Buffer was added to each tube and analyzed using the FACScalibur™ flow cytometer and CellQuest Pro software version 6.0 (BD Biosciences) within 1 h.

Western blotting. Western blotting was performed as previously described (22). Following treatment with sinomenine for 48 h, A549 cells were lysed in radioimmunoprecipitation assay lysis buffer (Applygen Technologies, Inc., Beijing, China). The cell debris was removed by centrifugation (15 min, 12,000 x g; Eppendorf, Hamburg, Germany), and the supernatant was stored at -80°C. Protein concentrations were estimated using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.).

Cell lysates (20 µg per lane) were subjected to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (Marker: Amresco, LLC, Solon, OH, USA; Electrophoretic and transfer equipment: Bio-Rad Laboratories, Inc., Hercules, CA, USA) and subsequently transferred to nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked in 5% skimmed milk, or bovine serum albumin (BSA; Vivantis Technologies, Oceanside, CA, USA) for phosphorylated proteins, in Tris-buffered saline with Tween 20 (50 mM Tris, 150 mM NaCl and 0.05% Tween 20), and serially incubated with primary antibodies at 4°C overnight and secondary antibodies for 1 h at room temperature. The antibodies used were as follows: Rabbit monoclonal anti-JAK2 (dilution, 1:1,000; catalog no., 3230), anti-STAT3 (dilution, 1:1,000; catalog no., 12640), anti-phosphorylated (p)-STAT3 (dilution, 1:1,000; catalog no., 9145), anti-β-actin (dilution, 1:1,000; catalog no., 4970), anti-Snail (dilution, 1:1,000; catalog no., 3879), anti-vimentin (dilution, 1:1,000; catalog no., 5741), anti-E-cadherin (dilution, 1:1,000; catalog no., 3195) (Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-N-cadherin (1:1,000; catalog no., 180224; Thermo Fisher Scientific, Inc.) antibodies, and horseradish peroxidase-linked anti-rabbit (catalog no., 7054) or anti-mouse (catalog no., 7076) immunoglobulin (Ig)G antibodies (dilution, 1:2,000; Cell Signaling Technology, Inc.). The bands were visualized using a chemiluminescence reagent (Applygen Technologies, Inc.) and recorded with a ChemiDoc™ XRS imaging system (Bio-Rad Laboratories, Inc.). The band densities were quantified using β-actin as a loading control, and analyzed using Image J (https://imagej.nih.gov/ij/).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The extraction of 5 mg total RNA from the A549 cells was performed using TRIzol® reagent (Thermo Fisher Scientific, Inc.). The concentration and purity of the extracted RNA were determined with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.), while electrophoresis was conducted to verify its integrity. A 2% agarose gel was used, the markers were supplied by Amresco, LLC, and the electrophoretic and visualization equipment were from Beyotime Institute of Biotechnology (Jiangsu, China).

To prepare the reaction master mix, 2 ml 10X RT buffer, 4 ml 25 mM MgCl2, 2 ml 0.1 M dithiothreitol and 1 ml RNAaseOUT were combined. The reaction mixture was added to the RNA/ primer mixture, mixed briefly, and then incubated at room temperature for 2 min. SuperScript II RT (1 ml; 50 units) was added each tube, mixed and incubated at 25°C for 10 min. Tubes were incubated at 42°C for 50 min, heat inactivated at 70°C for 15 min, and then chilled on ice. RNase H (1 ml) was added and incubated at 37°C for 20 min. The first strand of complementary DNA (cDNA) was synthesized by RT using the High-Capacity RNA-to-cDNA kit (Thermo Fisher Scientific, Inc.) stored at -20°C until use. qPCR was performed using TaqMan® Gene Expression Master Mix (Thermo Fisher Scientific, Inc.), template cDNA and primers. The primers were as follows: STAT3-RT5, 5'-CATCATGGG CTTTATCGTAAAGGAC-3' and STAT3-RT3, 5'-GTCATTGGTGATTGC7CGAGGTGT-3'; E-cadherin-RT5, 5'-CCC
ACCACGTACAGGGTC-3' and E-cadherin-RT3, 5'-CTG GGGTATTGGGGGCACTC-3'; N-cadherin-RT5, 5'-GCC GAGGAGACCAGGA-3' and N-cadherin-RT3, 5'-TAG TTGGGCTCCGGAGTG-3'; GAPDH forward, 5'-TGC ACCACCACTGTTAGC-3 and reverse, 5'-GCGATGGAC TGTTGGCTAGG-3'.

To prepare the mixture, 12.5 ml SYBR Green Mix (2X), 0.2 ml cDNA, 1 ml primer pair mix (5 pmol/ml each primer) and 11.3 ml H2O were combined. The total volume of each combined reaction mixture was 20 µl. Gene-specific, fluorogenic RT-qPCR for STAT3, E-cadherin, N-cadherin and glyceraldehyde 3-phosphate dehydrogenase was performed using a 3PrimeX Progene thermal cycler (Technie; Bibby Scientific Limited, Stone, UK). The thermocycling protocol was as follows: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 sec, 60°C for 30 sec and 72°C for 30 sec, 40 cycles; then 72°C for 10 min, 1 cycle. The results were normalized according to the method by Liu et al (23). The ABI Prism SDS 7300 (Thermo Fisher Scientific, Inc.) was used for quantification and the results were viewed and analyzed with Applied Biosystems 7500 Fast system (Thermo Fisher Scientific, Inc.). The assay was repeated 3 times.

Immunofluorescence. A549 cells were treated with 1.0 mM sinomenine for 24 h and then fixed in 4% paraformaldehyde (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) for 20 min at room temperature. The samples were washed 2 times in phosphate-buffered saline (PBS) to remove residual paraformaldehyde. Cells were permeabilized with 0.1% Triton X-100 made in PBS solution for 15 min, and then washed 3 times with PBS. Subsequent to blocking with 2% BSA for 1 h, cells were washed with PBS and BSA prior to being incubated with anti-STAT3 (1:500), anti-E-cadherin (1:500), anti-N-cadherin (1:500) or anti-vimentin (1:500) primary antibodies overnight at 4°C. Samples were then washed 5 times with PBS and BSA, followed by incubation with anti-rabbit or anti-mouse IgG secondary antibodies for 1 h at room temperature. Cells were then stained with 4,6-diamidino-2-phenylindole (Santa Cruz Biotechnology, Inc.) and mounted with anti-fading agent. Immunofluorescence was analyzed using the widefield high-content screening system ImageXpress® Micro XLS (Molecular Devices, LLC, Sunnyvale, CA, USA).

Statistical analysis. All experiments were performed three times unless otherwise stated, and data are presented as the mean ± standard deviation. Statistical significance was evaluated using one-way analysis of variance, followed by Fisher's least significant difference test. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS software version 18.0 (SPSS, Inc., Chicago, IL, USA).

Results

Sinomenine reduces A549 cell viability. To determine the effect of sinomenine on A549 cell viability, cells were treated with various concentrations of sinomenine (0-2 mM) for 24-72 h. The results demonstrated that sinomenine-treated cells exhibited a decreased cell count compared with untreated cells, and the inhibitory effect was dose-dependent (Fig. 1). As a positive control, cucurbitacin I (0.25 µM) was used, which significantly reduced the number of A549 cells (P<0.05) (Fig. 1).

Sinomenine induces A549 cell apoptosis. To determine whether the decreased viability of A549 cells following sinomenine treatment occurs as a result of apoptosis, Annexin V-FITC/PI staining was performed. As presented in Fig. 2A, sinomenine induced apoptosis in a dose- and time-dependent manner in A549 cells. The minimum dose of sinomenine required to induce apoptosis was 0.25 mM, while 1 mM sinomenine produced a similar effect to that caused by 0.25 µM cucurbitacin I (Fig. 2B and C). These results suggest that sinomenine-induced apoptosis may result in decreased cell viability.

Sinomenine regulates the protein expression of JAK2, STAT3 and EMT markers. To investigate the mechanisms underlying the biological effects of sinomenine on A549 cells, the upstream and downstream targets of STAT3 signaling were examined in A549 cells treated with sinomenine for 48 h by western blotting. The results demonstrated that sinomenine and cucurbitacin I downregulated the expression of JAK2, STAT3, p-STAT3, Snail, N-cadherin and vimentin compared with the untreated controls, while E-cadherin expression was upregulated (Fig. 3).

To further confirm the effect of sinomenine on the STAT3 signal transduction pathway, the messenger (m)RNA expression of STAT3, E-cadherin and N-cadherin was examined by RT-qPCR. The results demonstrated that the mRNA levels of STAT3 and N-cadherin were significantly reduced in the A549 cells following treatment with sinomenine and cucurbitacin I, whereas the level of E-cadherin mRNA was markedly increased (P<0.05) (Fig. 4). These results indicate that sinomenine may interfere with EMT in A549 cells by reducing the expression levels of the functional targets of the STAT3 signal transduction pathway.

Sinomenine prevents the invasion of A549 cells. To examine whether sinomenine affects the invasion of A549 cells,
biomarkers for EMT were examined by immunofluorescence. It was observed that E-cadherin staining under the plasma membrane was significantly increased in the A549 cells treated with sinomenine compared with the untreated control cells, whilst STAT3, N-cadherin and vimentin exhibited a decreased level of staining (Fig. 5). These results are consistent with the aforementioned western blotting and RT-qPCR data, and strongly suggest that sinomenine is able to attenuate A549 cell invasion through regulation of the STAT3 signaling pathway.

Discussion

The present study observed that sinomenine induced strong cytotoxicity, as indicated by decreased cell viability and apoptosis induction in A549 human lung adenocarcinoma cells. These results are consistent with previous observations in liver, breast and colon tumor cells (13,24,25).

STAT3 is a key transcription factor that is widely expressed in various tissues and cell types, and is primarily activated by the JAK-STAT and mitogen-activated protein kinase signal transduction pathways (26). Increasing evidence suggests that STAT3 is involved in proliferation, differentiation, invasion, metastasis, angiogenesis and resistance to apoptosis (27). The reported abnormal upregulation of STAT3 in hematological malignancies and solid tumors, including leukemia, hepatoma, and lung, prostate and breast cancer (28-32), indicates that STAT3 is important in the pathogenesis of such tumors.

Figure 2. Effect of sinomenine on A549 cell apoptosis. A549 cells were treated with sinomenine (0.125, 0.25, 0.5, 1.0 and 2.0 mM) or cucurbitacin I (0.25 µM) for 24 and 48 h, and apoptosis was measured by Annexin V/propidium iodide staining and analyzed by flow cytometry. (A) Representative scatter plots for apoptotic cells. (B) Percentage of apoptotic cells following treatment with sinomenine for 24 h. (C) Percentage of apoptotic cells following treatment with sinomenine for 48 h. Data are expressed as the mean ± standard deviation (n=3). *P<0.05 vs. untreated control. PI, propidium iodide; FITC, fluorescein isothiocyanate.

Figure 3. Effect of sinomenine on the expression of proteins involved in STAT3 signaling and EMT. Following treatment with sinomenine or cucurbitacin I for 48 h, the expression of proteins involved in the STAT3 signal transduction pathway and EMT were analyzed by western blotting. Band densities were quantified using Image J and adjusted to that of the corresponding loading control. STAT3, signal transducer and activator of transcription 3; EMT, epithelial-mesenchymal transition.
With regard to sinomenine, it has been reported that the drug possesses immunosuppressive properties, such as inhibiting the nuclear translocation of NF-κB (33). Notably, STAT3 and NF-κB interact and crosstalk between their associated pathways (34,35). The present study attempted to clarify whether the growth inhibition of A549 cells caused by sinomenine is mediated through the regulation of the STAT3 signaling pathway. The results demonstrated that STAT3 expression and activation were significantly suppressed in A549 cells following sinomenine treatment, which suggested that the
inhibition of STAT3 signaling resulted in growth inhibition of A549 cells.

During the process of EMT, epithelial cells lose polarity and gain cell motility, subsequently resulting in cell invasion (36-39). A number of studies have reported that EMT is involved in tumor invasion, metastasis and chemoresistance (36,37). During tumorigenesis, epithelial-type markers, including β-catenin, E-cadherin and cytokeratin, are typically downregulated, while mesenchymal markers such as N-cadherin and vimentin are upregulated (40). Therefore, understanding how to effectively restrain the process of EMT is vital for successful treatment of cancer. In the current study, it was observed that sinomenine reversed the protein expression of EMT biomarkers, indicating that sinomenine inhibited cell invasion. In addition, sinomenine may inhibit EMT through the regulation of STAT3 and its downstream target, Snail. It has been demonstrated that STAT3 is required for EMT via upregulation of the downstream gene Snail (41). Snail is able to directly inhibit the expression of E-cadherin, and subsequently interacts with the COOH-terminal region and the S'-CACCTG-3' motif in the E-cadherin promoter sequence to activate EMT (42,43). Yadav et al (41) reported that EMT may be induced by Snail, which is activated by the JAK/STAT3 signaling pathway, in head and neck tumor cells, thus resulting in tumor metastasis.

In conclusion, the present study demonstrated that sinomenine affects apoptosis, and inhibits tumor cell death and invasion by suppressing the activation of the STAT3 signaling pathway in A549 cells. To the best of our knowledge, the present study is the first to report that sinomenine is able to reverse EMT changes in A549 cells. These results may aid the understanding of the underlying mechanisms of sinomenine in treating non-small cell lung cancer.

Acknowledgements

The current study was supported by the National Natural Science Foundation of China (Beijing, China; grant nos. 81273718 and 81403346) and the China Postdoctoral Science Foundation (Beijing, China; grant no. 2014M550132).

References

1. Yan T, Okayama T, Fukuyama S and Machara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol 5: 1048-1054, 2014.
2. Pirker R: Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. Transl Lung Cancer Res 3: 305-310, 2014.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: TheIASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
4. Byron E and Pinder-Schenk M: Systemic and targeted therapies for early-stage lung cancer. Cancer Control 21: 21-31, 2014.
5. Akbari-Birgani S, Paranjothy T, Zuse A, Janikowski T, Cieslar-Pobada A, Likus W, Urasinska E, Schweizer F, Gavhari S, Klonsich T and Los MJ: Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discov Today 21: 836-842, 2016.
6. Brower V: Back to nature: Extinction of medicinal plants threatens drug discovery. J Natl Cancer Inst 100: 838-839, 2008.
7. Li JW and Vederas JC: Drug discovery and natural products: End of an era or an endless frontier? Science 325: 161-165, 2009.
8. Zhu Q, Sun Y, Zhu J, Fang T, Zhang W and Li JX: Antinociceptive effects of sinomenine in a rat model of neuropathic pain. Sci Rep 4: 7270, 2014.
9. Qian L, Xu Z, Zhang W, Wilson B, Hong JS and Flood PM: Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation 4: 23, 2007.
10. Koi T, Wu PY, Mak NK, Fan TP, Liu L and Wong RN: The anti-angiogenic effect of sinomenine. Angiogenisis 8: 3-12, 2005.
11. Li XJ, Yue PY, Ha WY, Wong DY, Tin MM, Wang PX, Wong RN and Liu L: Effect of sinomenine on gene expression of the IL-1 beta-activated human synovial sarcoma. Life Sci 79: 665-673, 2006.
12. Jiang T, Zhou L, Zhang W, Qu D, Xu X, Yang Y and Li S: Effects of sinomenine on proliferation and apoptosis in human lung cancer cell line NCI-H460 in vitro. Mol Med Rep 5: 51-56, 2010.
13. Lu XL, Zeng J, Chen YL, He PM, Wen MX, Ren MD, Hu YN, Lu GF and He SX: Sinomenine hydrochloride inhibits human hepatocellular carcinoma cell growth in vitro and in vivo: Involvement of cell cycle arrest and apoptosis induction. Int J Oncol 42: 229-238, 2013.
14. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nat Rev 45: 454-464, 2004.
15. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation and cancer. Cell 140: 883-899, 2010.
16. Kuraishi Y, Karin M and Grivennikov SI: Tumor promotion via injury- and death-induced inflammation. Immunity 35: 467-477, 2011.
17. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
18. Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
19. He G and Karin M: NF-xB and STAT3 - key players in liver inflammation and cancer. Cell Res 21: 159-168, 2011.
20. Bosch-Barrera J and Menendez JA: Siblinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev 41: 540-546, 2015.
21. Yu H, Lee H, Herrma nn A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer 14: 736-746, 2014.
22. Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J and Arlinghaus RB: Bcr: A negative regulator of the Bcr-Abl oncoprotein. Oncogene 18: 4416-4424, 1999.
23. Liu Z, Duan ZJ, Chang JY, Zhang ZF, Chu R, Li YL, Dai KH, Mo GQ and Chang QY: Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression. PLoS One 9: e89560, 2014.
24. Li X, Wang K, Ren Y, Zhang L, Tang XJ, Zhang HM, Zhao CQ, Liu PJ, Zhang JM and He JI: MAPK signaling mediates sinomenine hydrochloride-induced human breast cancer cell death via both reactive oxygen species-dependent and -independent pathways: An in vitro and in vivo study. Cell Death Dis 5: e1356, 2014.
25. Zhang JX, Yang ZR, Wu DD, Song J, Guo XF, Wang J and Dong WG: Suppressive effect of sinomenine combined with 5-fluorouracil on colon carcinoma cell growth. Asian Pac J Cancer Prev 15: 706-714, 2014.
26. Spitzner M, Ebner R, Wolff JA, Ghadimi BM, Wianends J and Grade M: STAT3: A novel molecular mediator of resistance to chemoradiotherapy. Cancers (Basel) 6: 1986-2011, 2014.
27. Siveen KS, Tikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta 1845: 136-154, 2014.
28. Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Imanishi K, Kanatsu S, Nomoto K, Suzuki A, Obata M, Hara H, Kishida K, Yanagisawa A, Yamauchi T, Fujii H, Yamaguchi T, Kuraishi A, Komatsu S, Ito T and Kawasaki S: STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci 105: 342-346, 2014.
29. Geletu M, Guy S and Raptis L: Effects of SRC and STAT3 pathway on cell growth. Oncotarget 6: 22377-22384, 2015.
30. Chang JY, Zhang ZF, Yang Y and Wang J: DTG: A natural way of targeting transcription factors for cancer therapy. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol 5: 1048-1054, 2014.
31. Akbari-Birgani S, Paranjothy T, Zuse A, Janikowski T, Cieslar-Pobada A, Likus W, Urasinska E, Schweizer F, Gavhari S, Klonsich T and Los MJ: Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discov Today 21: 836-842, 2016.
32. Brower V: Back to nature: Extinction of medicinal plants threatens drug discovery. J Natl Cancer Inst 100: 838-839, 2008.
31. Hsu FN, Chen MC, Lin KC, Peng YT, Li PC, Lin E, Chiang MC, Hsieh JT and Lin H: Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser727 on STAT3 in prostate cancer cells. Am J Physiol Endocrinol Metab 305: E975-E986, 2013.
32. Ibrahim SA, Hassan H, Vilardo L, Kumar SK, Kumar AV, Kelsch R, Schneider C, Kiesel L, Eich HT, Zucchi I, et al: Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One 8: e85737, 2013.
33. Zhao Y, Li J, Yu K, Liu Y and Chen X: Sinomenine inhibits maturation of monocyte-derived dendritic cells through blocking activation of NF-kappa B. Int Immunopharmacol 7: 637-645, 2007.
34. De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, et al: Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-xB to promote colorectal cancer cell growth. Oncogene 34: 3493-3503, 2015.
35. Levy DE and Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662, 2002.
36. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226, 2009.
37. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216, 2010.
38. Micalizzi DS, Farabaugh SM and Ford HL: Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15: 117-134, 2010.
39. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
40. Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22: 194-207, 2012.
41. Yadav A, Kumar B, Datta J, Teknos TN and Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 9: 1658-1667, 2011.
42. Peinado H, Portillo F and Cano A: Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48: 365-375, 2004.
43. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.